StockWatch
·

Gretex Corporate Services Ltd Q2 FY27 Results

GCSLQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: None

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue75.60101.5%5.0%
Total Income76.52101.0%13.6%
Expenditure66.92214.4%37.5%
PBT9.6042.8%48.6%
Net Profit7.1544.1%44.7%
OPM12.72%32.94pp27.19pp
NPM9.34%24.28pp9.84pp
EPS1.9850.1%65.3%
View full financials

Core revenue fell 5% YoY and adjusted PAT fell 44.7% as operating margin collapsed from ~39.9% to ~12.7%, a clear deterioration in the sector's key profitability metric.

GCSL · Q2 FY27 · THE VERDICT

One listing, no margin cushion—and the market pricing in four more

Gretex delivered just one IPO in Q2 against guidance of 3–4, halving margins to 12.7%. Yet the stock trades near its all-time high, betting entirely on the four DRHP mandates and a strategic pivot to recurring advisory that's still unproven.

11 Nov 2026 · 6 min read
Q2 Reported PAT

₹7.1 Cr

−44.7% YoY

H1 Reported PAT

₹19.9 Cr

+43.2% YoY

H1 Other-income swing

₹13 Cr

₹1.5 Cr vs. −₹11.5 Cr prior year

Q2 EBITDA margin

12.7%

−27.1pt YoY

The headline reads like a collapse: Q2 profit down 45%, margins halved. But the real story is simpler—and riskier. Gretex delivered one IPO listing (Vama Wovenfab in September) against guidance of at least three to four. That single miss explains both the revenue decline and the margin fall. The market, however, is pricing in redemption: the stock trades near its all-time high of ₹800.8, betting that four DRHP-approved mandates will close in Q3 or Q4, and that a nascent pivot to recurring advisory revenue will eventually stabilize the lumpy deal-driven model. Neither assumption has been proven yet.

The H1 PAT story: reported vs. organic

The first half shows PAT growth of 43.2%, which looks like relief after Q2. But dig into the composition, and the picture shifts: H1 other income was ₹1.5 Cr against negative ₹11.5 Cr in the prior year—a ₹13 Cr favorable swing. Exclude that, and core operational profit is essentially flat YoY. Q2 itself carries no such cushion; it is the miss laid bare.

H1 FY27 PAT components, ₹ Cr
07.4314.8622.2919.9Reported1.5Other income18.4Adjusted (est.)
The ₹13 Cr other-income swing between H1 FY26 and H1 FY27 inflates reported PAT growth; underlying operational momentum is modest.

What management said vs. what held up

Management claims on the Q2 call, graded

Margin decline is only about lower turnover, not weakness

Correct: EBITDA margin fell 27.1 points due to one listing vs. expected ≥3–4. But evasive—the real risk is that the model is structurally lumpy; fewer mandates compress absolute margin cover.

Supported (but incomplete)

H1 PAT up 43.2%; solid operational progress

Inflated by ₹13 Cr other-income swing. Core operational PAT flat YoY. Not recurring.

Overstated

Building integrated capital markets business; post-listing advisory, AIF expansion

Articulated strategy; early execution (₹25 Cr AIF first close, Ahmedabad broking office, one preferential issue mandate). Highly conceptual; no revenue run-rate or ROI targets provided.

Partial

Primary market strong; ₹84,400 Cr mainboard fundraising in H1 FY27

Industry fact verified (+30% YoY, 71 mainboard IPOs vs. 55). But Gretex's core competency (SME segment) weakened: 137 SME listings (−12%) and ₹6,012 Cr fundraising (−11% YoY).

Supported (but context matters)

What changed on this call

  • IPO execution velocity downgraded: Q1 expected ≥3–4 Q2 listings; delivered 1 (Vama Wovenfab, Sep 22). 4 DRHP mandates filed but not closed; pipeline pushed to Q3–Q4.

  • Strategic pivot announced: Shift from transaction-led to recurring revenue (post-listing advisory retainers targeting ₹10 lakhs–₹1 crore monthly per client; AIF participation). First ₹25 Cr fund (Celestial Chakra Momentum) closed. Nascent; unquantified aggregate.

  • Segment exposure rebalancing: Mainboard IPOs strong (+30% fundraising, 71 listings H1 FY27). SME segment (Gretex's core) moderated (−12% listings, −11% fundraising). Gretex executed 1 SME listing; 4 mainboard mandates pending.

  • Margin sustainability risk heightened: EBITDA margin 39.8% (Q2 FY26, 16+ deals) → 12.7% (Q2 FY27, 1 deal). Structural lumpy-ness exposed; absolute margin cover halved.

The bull-bear ledger

  • Industry tailwind intact: Primary market strong (₹84,400 Cr mainboard raised H1 FY27, +30% YoY). Record fundraising environment creates runway for executed mandates.

  • Pipeline credibility in doubt: Q2 guidance of ≥3–4 listings missed; 1 delivered. 4 DRHP mandates cite 'maybe this quarter or next,' not certainty. Guidance credibility eroded.

  • Core SME segment weakness: SME IPO fundraising −11% YoY to ₹6,012 Cr. Gretex's historical strength vulnerable to competitive intensity and investor selectivity. Shift to mainboard adds scale risk (longer execution, lower fees per rupee raised).

  • Recurring revenue unproven at scale: Post-listing advisory and AIF strategies conceptually sound but early-stage. No revenue run-rate, cost base, or breakeven timeline disclosed. Transition risk material.

  • H1 momentum masks Q2 deterioration: H1 revenue +11.4% YoY and H1 PAT +43.2% (other-income inflated). Q2 in isolation: revenue −5%, PAT −44.7%. Sequential quarter-on-quarter collapse in profit (−44.1% QoQ PAT) despite +101.6% revenue QoQ recovery.

Risks, ranked by how much they should concern a holder

Material risks to execution and valuation

Deal pipeline execution slippage (4 DRHP mandates) and no closure guarantee

High

Q2 missed ≥3–4 guidance badly (delivered 1). 4 DRHP mandates (Sky, Tenty, Abacus, Oremet) remain pending with only 'maybe this quarter or next' visibility. A 3–6 month delay pushes material revenue into H2 FY27 or even FY28, impacting FY27 consensus and extending margin pressure.

Lumpy, deal-dependent revenue and margin volatility; structural not cyclical

High

EBITDA margin collapsed 27.1 points (39.8% → 12.7%) from one listing shortfall. Absolute margin cover halved. Recurring advisory and AIF are nascent. If the deal model cannot be stabilized by recurring revenue within 12–18 months, valuation multiple re-rating downward becomes likely.

SME IPO segment moderation; competitive intensity and pricing pressure

Medium

H1 FY27 SME fundraising −11% YoY to ₹6,012 Cr (137 listings vs. 156). Gretex's core competency vulnerable. Shift to mainboard (4 pending mandates) adds execution complexity and may lower fee margins per rupee raised despite larger deal sizes.

Other income volatility masks core profit weakness

Medium

H1 other income ₹1.5 Cr vs. −₹11.5 Cr prior year (₹13 Cr favorable swing). Inflated H1 PAT by ≈₹13 Cr. Not recurring. Q2 carries no such cushion. If other income normalizes, FY27 PAT could disappoint consensus.

Recurring revenue model unproven; no quantified run-rate or ROIC

Medium–High

Post-listing advisory targeting ₹10 lakhs–₹1 crore monthly per client (unquantified aggregate), and AIF participation (₹25 Cr first close, ₹50+ Cr target corpus). No revenue timeline, cost base, or breakeven. Transition risk high; new revenue streams could be delayed or underdeliver.

How the market is positioned

The stock trades at ₹783, just 2.2% below its all-time high of ₹800.8, with an RSI of 73.9 (overbought territory). This is a bullish bet on execution. Over the past year, the stock has rallied +245.7% from its 52-week low of ₹226.5, and it sits well above its 20-day (₹753.69) and 50-day (₹679.67) averages—classic strong-trend structure. Yet the quarter itself was a miss: guidance for ≥3–4 listings, delivered 1. The valuation move suggests the market has already priced in the four DRHP closures and the pivot to recurring advisory. There is little room for further disappointment without a sharp pullback.

Ownership tells a cautious story: FII holdings rose 0.89 percentage points to 1.99% in Q1 FY27 (from 1.10% in Q4 FY26), a modest incremental buy. Promoter stake remains steady at 61.64%. Domestic institutional investors (DII) are absent (0.00%). In the bulk/block deals over the past six months, Mansukh Securities has dominated activity—trading volume in late October 2026 near the highs (₹723–₹737 range) suggests tactical long-short flows rather than strategic institution conviction. The pattern—small FII buy-ins, promoter hold steady, tactical shorting near highs—implies that smart money is waiting for Q3–Q4 pipeline delivery before committing capital. The market's bullish price structure masks underlying caution.

The debate

What to watch next

The three things that resolve the debate
  • 1 · Q3–Q4 DRHP listing closures (Sky, Tenty, Abacus, Oremet)

    If 2+ mandates close in Q3, expect EBITDA margin to recover toward 25–30% and PAT to rebound materially. Each closure is binary; no closure by Dec 31, 2026 signals either execution failure or deeper market headwinds, prompting consensus cuts and re-rating risk.

  • 2 · Post-listing advisory retainer revenue run-rate and AIF 2nd close

    Post-listing mandates must show traction (retainer customers, monthly fee run-rate) by end-H1 FY27 Q4 results (Sep 2027). The ₹25 Cr first close is a start; a ₹50+ Cr target corpus 2nd close signals investor confidence and materially de-risks the recurring-revenue transition. Absence of progress on both fronts will be read as execution risk on the strategic pivot.

  • 3 · FY27 and FY28 guidance revision (revenue, PAT, margin targets)

    Management has given no quantified targets. By Q3 results, revised FY27 guidance and an FY28 revenue/margin outlook are necessary to repair credibility post-miss. If guidance remains unquantified, it signals management confidence deficit or intentional caution—either way, a red flag for execution.

Gretex is a step-change transformation in progress, not a steady franchise. Q2 was not a blip; it was the fragility of the deal-dependent model laid bare. The market is pricing in perfect execution on four pending mandates and a successful early-stage pivot to recurring advisory—both of which are uncertain. The stock has priced in the upside; the downside risk is material if closures slip or strategic initiatives disappoint. The number to track from here is the Q3–Q4 listing tally and the early run-rate of post-listing advisory retainer revenue. Execution must now happen. The call for strategic investors remains Hold pending clarity on the pipeline and momentum on recurring revenue. For tactical traders, the overbought technicals (RSI 73.9, near ATH) argue for waiting for a pullback to the 50-day moving average (₹679.67) or a concrete catalyst (a listed mandate) before re-entry.

Informational and educational content only. Not investment advice.